Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities
- 614 Downloads
Background: Psoriasis is associated with a variety of major physical and mental co-morbidities.
Objective: To assess the incremental burden of co-morbidities on patient-reported outcomes and evaluate the efficacy and safety of adalimumab in psoriasis patients with co-morbidities.
Study Design: Data were obtained from the initial 16-week, double-blind treatment period of REVEAL (Randomized controlled EValuation of adalimumab Every other week dosing in moderate to severe psoriasis triAL), a randomized, multicenter, phase III clinical trial.
Intervention: Patients with moderate to severe psoriasis were randomized in a 2 : 1 ratio to receive adalimumab 80 mg (two 40 mg injections administered subcutaneously) at baseline followed by one 40 mg injection every other week from week 1 to week 15 or placebo.
Main Outcome Measures: Clinical severity (Psoriasis Area and Severity Index [PASI]) and patient-reported outcomes (Dermatology Life Quality Index [DLQI], Short Form 36 [SF-36] health survey, Work Productivity and Activity Impairment [WPAI] questionnaire) were assessed during the trial. The effect of selected co-morbidities (i.e. hypertension, psoriatic arthritis, hyperlipidemia, obesity, depression, other forms of arthritis, diabetes mellitus, and other cardiovascular diseases) on patient-reported outcomes was evaluated using multivariate analysis of covariance models. Subgroup analyses were performed by co-morbidity type to statistically compare the clinical efficacy, patient-reported outcome benefits, and safety of adalimumab with placebo in the presence of these conditions.
Results: Study co-morbidities were each independently associated with significantly greater impairment on at least one general patient-reported outcome measured at baseline (all p < 0.05), with the exception of hyperlipidemia. During the 16-week study, adalimumab patients demonstrated significantly greater PASI 75 response rates (defined as a reduction of at least 75% in PASI scores from baseline) compared with placebo patients for all co-morbidity subgroups. Adalimumab provided consistent improvements in DLQI, SF-36 Physical Component Summary and Mental Component Summary scores, and WPAI total scores from baseline to week 16 within co-morbidity subgroups. Rates of serious adverse events (AEs), serious infectious AEs, and AEs leading to discontinuation were comparable between adalimumab and placebo for patients with co-morbidities.
Conclusions: Co-morbidities were associated with additionally impaired health-related quality of life and work productivity in patients with psoriasis. Adalimumab significantly improved efficacy and patient-reported outcomes and was well tolerated in patients with co-morbidities.
This analysis was funded by Abbott Laboratories. Alexa Kimball is an investigator and consultant for Abbott, Amgen, and Centocor, and Arielle Bensimon, Annie Guerin, Andrew Yu, and Eric Wu are employees of Analysis Group, Inc., an organization contracted by Abbott Laboratories to perform this analysis. Martin Okun, Yanjun Bao, and Parvez Mulani are employees of Abbott Laboratories and own stock and/or stock options in Abbott Laboratories. Shiraz Gupta is a former employee of Abbott Laboratories. Arbor Communications, Inc. provided editorial assistance on behalf of Abbott Laboratories.
- 1.Adams PF, Hendershot GE, Marano MA; Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the NationalHealth Interview Survey, 1996. Vital Health Stat 1999 Oct; 10 (200): 1–203Google Scholar
- 3.Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 Sep; 41 (3 Pt 1): 401–7Google Scholar
- 5.Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008 Nov; 59 (5): 772–80Google Scholar
- 6.Kimball AB, Gladman D, Gelfand JM, et al.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008 Jun; 58 (6): 1031–42Google Scholar
- 8.Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008 Apr; 7 (4): 373–7Google Scholar
- 9.Sterry W, Strober BE, Menter A; International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 Oct; 157 (4): 649–55Google Scholar
- 10.Leonard DG, O’Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978 Aug; 53 (8): 511–8Google Scholar
- 11.Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005 Oct; 53 (4): 573–7Google Scholar
- 12.Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005 Mar; 64 (Suppl. 2): ii14–7Google Scholar
- 13.Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderateto- severe psoriasis. Br J Dermatol 2008 Sep; 159 (3): 704–10Google Scholar
- 16.Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis: a structural equations modeling approach. Gen Hosp Psychiatry 2007 Mar-Apr; 29 (2): 134–40Google Scholar
- 17.Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008 Nov; 159 (5): 1116–23Google Scholar
- 18.Saurat JH, Stingl G, Dubertret L, et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 Mar; 158 (3): 558–66Google Scholar
- 19.Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 Jan; 58 (1): 106–15Google Scholar
- 20.Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 Mar; 158 (3): 549–57Google Scholar
- 22.Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006 Sep; 4: 71–82Google Scholar
- 23.Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 Nov; 4 (5): 353–65Google Scholar
- 24.Chao EL, Hall K. National compensation survey: occupational earnings in the United States, 2007 [online]. Available from URL: (http://www.bls.gov/ncs/ncswage2007.htm#Wage_Tables [Accessed 2008 Nov 11]Google Scholar
- 25.Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004 Dec; 151 (6): 1227–33Google Scholar